These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 30043658

  • 1. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 5. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 6. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
    Fronza M, Lorefice L, Frau J, Cocco E.
    Drug Des Devel Ther; 2021 Nov; 15():1993-2004. PubMed ID: 34007159
    [Abstract] [Full Text] [Related]

  • 7. Ozanimod: First Approval.
    Lamb YN.
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [Abstract] [Full Text] [Related]

  • 8. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 9. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS.
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
    Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
    [Abstract] [Full Text] [Related]

  • 11. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J.
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [Abstract] [Full Text] [Related]

  • 12. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 13. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 14. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug 24; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract] [Full Text] [Related]

  • 15. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G.
    Lancet Gastroenterol Hepatol; 2020 Sep 24; 5(9):819-828. PubMed ID: 32553149
    [Abstract] [Full Text] [Related]

  • 16. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study Group.
    N Engl J Med; 2021 Sep 30; 385(14):1280-1291. PubMed ID: 34587385
    [Abstract] [Full Text] [Related]

  • 17. Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sun Y, Yang Y, Wang Z, Jiang F, Chen Z, Wang Z.
    Front Pharmacol; 2020 Sep 30; 11():589146. PubMed ID: 33658933
    [Abstract] [Full Text] [Related]

  • 18. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.
    JAMA Neurol; 2016 Sep 01; 73(9):1089-98. PubMed ID: 27380540
    [Abstract] [Full Text] [Related]

  • 19. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM, Oh J.
    Neurodegener Dis Manag; 2021 Jun 01; 11(3):207-220. PubMed ID: 34011158
    [Abstract] [Full Text] [Related]

  • 20. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA.
    Mult Scler Relat Disord; 2021 Feb 01; 48():102673. PubMed ID: 33454584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.